In 2022, Novartis invested around $10 billion in overall research and development (R&D) and has already secured 23 approvals in the United States, European Union, China and Japan for new...
Globally as well as in India, rare or orphan diseases as they are also known, pose a significant threat not just to the public health system but also to the...
Amicus FOLD announced that the European Commission approved cipaglucosidase alfa, commercialized under the brand name Pombiliti, for treating late-onset Pompe disease (LOPD) in adults. Cipaglucosidase alfa is a long-term enzyme replacement...
New Delhi: The government has exempted all food and drugs imported for the treatment of all rare diseases from basic customs duty, a move that could potentially benefit 70-90 million...
Certain genetic conditions can cause symptoms in children that can’t yet be diagnosed, called Syndromes without a Name (SWAN). It is a term doctors sometimes use when children experience symptoms...
